Fuxiang Pharmaceutical: Passed the on-site inspection by the US FDA.

Fuxiang Pharmaceutical announced that the company accepted an on-site cGMP inspection by the U.S. Food and Drug Administration from August 11, 2025 to August 14, 2025. The inspection covered various GMP systems including quality system, material management system, production management system, equipment system, packaging and labeling system, and laboratory control system. The company received the on-site inspection report issued by the FDA, and the inspection was successfully passed with a VAI result. This was the company's third successful on-site cGMP inspection by the FDA, marking the company's quality system aligning with international standards, and demonstrating the company's qualification to continually provide commercial intermediates and active pharmaceutical ingredients for the U.S. and global markets.